Levoben

Quick links to important sections

Levoben

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levoben

Property Description
Active ingredients Levodopa and Benserazide
Form Oral tablets (standard or modified-release)
Pharmacological class Anti-Parkinson agent / Dopaminergic agent
Type Synthetic, fixed-dose combination
Route of administration Oral

What Type of Medicine is Levoben and What is its Purpose?

Levoben is a synthetic, fixed-dose combination product classified as an Anti-Parkinson agent belonging to the dopaminergic agent pharmacological group. The medication's general purpose is to help restore chemical balance in the brain by managing the deficiency of the vital neurotransmitter dopamine. Levoben, like other preparations of the same active ingredient combination, is clinically recognized for providing replacement therapy for dopamine precursors in the central nervous system.

This medication is intended for systemic treatment and is typically administered through the oral route in the form of tablets. As a combination preparation, Levoben’s core design integrates two distinct active ingredients to achieve maximal therapeutic effect by ensuring the primary component can reach the central nervous system (CNS) effectively.

Composition: The Dual Role of Levodopa and Benserazide

The composition of Levoben features a synergistic combination of two core active ingredients: Levodopa (L-Dopa) and Benserazide. Levodopa functions as the essential prodrug and dopamine precursor, while Benserazide acts as a DOPA decarboxylase inhibitor. In this fixed-dose combination, the role of Benserazide is specifically to prevent the premature metabolic breakdown of the Levodopa outside the brain.

This strategic pairing is critical because Levodopa is extensively metabolized in the body before it can cross the blood-brain barrier. Benserazide, which does not effectively cross the barrier itself, provides the necessary peripheral protection mechanism.

Understanding Levoben’s Core Function

Levoben’s fundamental action is centered on providing a highly efficient means of replenishing the brain’s diminished supply of the dopamine precursor. The medication’s core function is achieved by the protected mechanism that limits the loss of Levodopa in the peripheral circulation. This therapeutic approach is a long-established standard in neurology. By maximizing the delivery of the precursor to the brain, the combination supports the goal of improving motor function and reducing associated movement difficulties linked to the chemical imbalance.

Regulatory References

  1. Anti-Parkinson agent
  2. dopaminergic agent
  3. NIH MedlinePlus
  4. Levodopa and Benserazide
  5. prodrug
  6. DOPA decarboxylase inhibitor

What side effects are possible with Levoben?

Possible Side Effects and Safety Information

The official safety profile for Levoben (levobunolol ophthalmic solution) is structured around reported adverse reactions and safety restrictions documented in government regulatory sources, which define conditions where the medication should not be used.

Adverse Reaction Classifications

Adverse reactions are officially grouped by the frequency observed in clinical studies and by the body system affected:

  • Common Reactions (10% to 30%): The most frequently reported adverse effects involve the eye and are often transient, such as stinging, burning upon instillation, and conjunctival injection.
  • Uncommon Reactions (1% to 10%): These include other Eye Disorders like corneal staining, keratitis, and blurred vision, as well as systemic effects such as headache, dizziness, bradycardia, and nausea.
  • Rare Reactions (<1%): Severe respiratory reactions, including dyspnea (shortness of breath) and asthma exacerbation, have been documented.

Serious Adverse Reactions and Systemic Absorption

As a non-selective beta-blocker applied topically, the potential for systemic absorption necessitates documenting the risk of serious adverse reactions associated with oral beta-adrenergic blocking agents. These can include severe cardiovascular events (such as overt cardiac failure, third-degree heart block, or severe bradycardia) and significant respiratory issues (such as bronchospasm).

Safety-Related Restrictions and Considerations

The medication is contraindicated and must not be used in individuals with specific pre-existing conditions, particularly severe pulmonary or cardiac impairments. These include bronchial asthma, a history of asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, and overt cardiac failure. The safety and effectiveness of Levoben have not been established in pediatric patients according to regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

Levoben overdose is primarily characterized by severe manifestations affecting the cardiovascular and central nervous systems, according to official regulatory documentation. Documented clinical signs include significant cardiac arrhythmias, such as tachycardia, and pronounced abnormal involuntary movements (dyskinesia). Other documented presentations may involve hypotension, confusion, insomnia, nausea, and vomiting.

Required Emergency Action

Due to the risk of life-threatening cardiac and neurological outcomes, the official labeling mandates that immediate medical attention or emergency services must be contacted immediately if an overdose is suspected. Urgent hospitalization is required for the necessary observation and management of acute toxicity.

Management and Constraints

Regulatory guidance states that no specific antidote is known for Levoben overdose. Therefore, clinical management is focused on providing symptomatic and supportive treatment. This includes immediate measures such as gastric lavage or administration of activated charcoal if the ingestion was recent, alongside essential ECG monitoring and continuous observation of vital signs. Official documents also note that patients with pre-existing cardiovascular disorders face an increased risk of severe cardiac complications following an overdose.

Therapeutic Uses of Levoben

What Levoben Treats: Main Uses and Benefits

Levoben, which contains the active ingredient levobunolol, is an ophthalmic (eye) medication primarily used to support the management of conditions related to elevated intraocular pressure (IOP). The primary focus of its use is on these two conditions. The medication addresses IOP in patients diagnosed with chronic open-angle glaucoma and ocular hypertension.

The associated therapeutic benefit addresses the elevated pressure within the eye, which is a crucial medical goal in managing chronic conditions that can affect the optic nerve. This supports the management of a key risk factor for vision changes. For individuals managing glaucoma, the reduction of IOP is a key strategy for long-term care.

“Supporting the reduction of intraocular pressure is the key therapeutic objective in these ophthalmic scenarios.”

Quick Fact: Focus on Elevated IOP

Levoben is categorized as an eye drop used to help address elevated eye pressure as part of a therapeutic regimen for chronic patients.

Regulatory References

  1. National Library of Medicine DailyMed Overview

Eligibility and Restrictions for Use

Levoben’s eligibility for use is strictly determined by official regulatory documents, prohibiting its use in several specific populations. The medicine is contraindicated for patients with known hypersensitivity to levodopa, benserazide, or any excipients. Use is also strictly prohibited for individuals taking non-selective MAO inhibitors and for patients diagnosed with malignant melanoma or closed-angle glaucoma.

Eligibility is heavily restricted by age, as the medicine is contraindicated in patients under 25 years of age to ensure that skeletal development is complete. Furthermore, the drug must not be used by pregnant women or by women of childbearing potential who are not using adequate contraception.

Severe, non-compensated organ function also prevents eligibility. The medicine is contraindicated in patients with decompensated endocrine, renal, hepatic, or severe cardiac function, as well as in those with psychiatric diseases involving a psychotic component. Special caution is required for patients undergoing surgery with halothane (requiring discontinuation 12–48 hours prior) and for those with risk factors for orthostatic hypotension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Levodopa/Benserazide (Levoben) documents specific restrictions and interaction patterns with other substances, primarily categorized by the risk of potentiation, antagonism, or altered drug exposure.

Formal Regulatory Restrictions

Co-administration with non-selective Monoamine Oxidase (MAO) inhibitors is contraindicated due to the significant risk of a hypertensive crisis. Treatment with non-selective MAO inhibitors must cease at least 14 days prior to initiating Levoben. Similarly, the simultaneous use of selective MAO-A and selective MAO-B inhibitors is prohibited, as this combination also results in non-selective inhibition.

Documented Pharmacokinetic Changes

Substances that alter the plasma concentration of levodopa are officially recognized. Iron Salts (Ferrous Sulphate) reduce the maximum plasma concentration (Cmax) and AUC of levodopa by 30% to 50% due to chelation, requiring dose separation of 2–3 hours. Conversely, COMT inhibitors (e.g., Entacapone) are documented to increase the bioavailability (AUC) of levodopa. The ingestion of Dietary Protein with the standard tablet formulation also reduces levodopa's Cmax and overall absorption.

Pharmacodynamic and Procedural Constraints

Antipsychotic agents that block dopamine receptors may counteract the medicine's dopaminergic action. Co-administration with Sympathomimetics risks potentiating their effect, increasing the potential for cardiovascular side-effects. Furthermore, Levoben must be discontinued 12–48 hours before the administration of Halothane general anesthesia due to the risk of blood pressure fluctuations.

Mechanism of Action

How Levoben Works


The mechanism of Levoben relies on a dual action to maximize the availability of the precursor Levodopa within the central nervous system (CNS). First, Benserazide acts as a competitive inhibitor of the enzyme Aromatic-L-Amino-Acid Decarboxylase (AADC) in the periphery, blocking the premature conversion of Levodopa to Dopamine outside the brain. This peripheral protection facilitates the subsequent transport of a greater quantity of intact Levodopa across the Blood-Brain Barrier (BBB).

Once inside CNS neurons, Levodopa is rapidly converted by intrinsic AADC into the active neurotransmitter, Dopamine. This Dopamine is released into the synapse, where it acts as an agonist binding to and stimulating the D1 through D5 Dopamine receptors in the striatum. This cascade of neurotransmitter synthesis modulates the signaling dynamics within the nigrostriatal pathway and the motor control circuitry, directly influencing the output of motor control. The functionality of this central conversion, however, is mechanistically dependent on the integrity of the remaining AADC-containing neurons.

Dosage and Administration Information

Levoben (levobunolol) is administered exclusively through the topical ophthalmic route as a solution intended for application to the surface of the eye. This administration pattern is typically long-term, defining its use in managing chronic conditions. The usage protocol defines dosing based on the specific concentration utilized.

For the 0.5% concentration, the typical regimen begins with one to two drops administered to the affected eye(s) once daily. If the clinical response requires further adjustment, the frequency may be increased to one to two drops twice daily. The 0.25% solution is generally administered as one to two drops twice daily.

When applying the solution, several procedural conditions must be observed. If any concurrent topical eye medications are used, the instillation of Levoben must be separated by at least several minutes to ensure proper delivery. Furthermore, individuals using soft contact lenses must remove them prior to administration and wait at least 15 minutes before reinserting them. To support optimal delivery and reduce systemic exposure, gently closing the eye or using nasolacrimal occlusion (applying pressure to the tear duct) for one to two minutes after instillation is advised.

Regarding population-specific use, safety and efficacy standards have not been established for pediatric patients. In contrast, no specific limitations or dose adjustments for older adults have been identified.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes findings from clinical research and trials involving the drug combination Levoben (referencing studies on Levodopa/Benserazide or similar combinations, particularly in the context of Parkinson's Disease, as per the established medical profile).

Research Focus and Measurement

Research has examined the effects of this combination on clinical endpoints used to measure motor and non-motor symptoms in participants with Parkinson's Disease (PD). Studies have investigated whether treatment is associated with a decrease in active symptoms, as measured by clinical scales such as the Unified Parkinson's Disease Rating Scale (UPDRS) scores. The duration of treatment was specified within the study protocols.

Studies on Drug Action

Clinical and preclinical studies explore the mechanism of action of the Levodopa component, which is a precursor to the neurotransmitter dopamine. This mechanism involves its conversion to dopamine in the brain to compensate for deficits observed in PD. This area is often an area of preclinical and early-stage clinical investigation.

  • Laboratory Markers: Studies investigated specific laboratory markers to track changes in participant health.
  • Disease Activity Indices: Studies utilized clinical rating scales (e.g., UPDRS) to track motor symptoms (e.g., tremor, rigidity, bradykinesia) and daily living activities over the course of the research period. Research evaluated changes in participant-reported quality of life and discomfort scores.

Comparison Studies: Combination vs. Monotherapy

Research has compared combination therapy with monotherapy (Levodopa alone) in managing symptoms of PD.

  • Clinical Efficacy: Comparison studies often focused on the extent of change in motor scores and the proportion of participants achieving clinical improvement at defined time points.
  • Safety Profile: Trials documented and compared the frequency of adverse events and reasons for discontinuation between the combination group and the monotherapy group.

Safety and Tolerability Data

Safety assessments in clinical trials monitor the occurrence of adverse events across all participants. Studies typically include reporting of the severity of any side effect and its relationship to the study treatment.

  • Discontinuation: Clinical trials documented that participants experiencing serious side effects discontinued the course. The documentation of participant discontinuation due to adverse events included tracking the types of events that occurred.
  • Serious Adverse Events: The frequency of serious adverse events (SAEs) was tracked and compared between the combination therapy group and the control group in clinical trials.

Key Studies & References

  1. NICE Guideline NG71: Parkinson's disease in adults (Guidance on diagnosis and management).
  2. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
  3. Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON (NCT02769793) - Study Details.

Frequently Asked Questions (FAQ)

Common questions about Levoben (FAQ)


Q: Does Levoben interact with common over-the-counter pain relievers?

Regulatory documents primarily list interactions with specific drug classes, such as iron salts and sympathomimetics. The official product information does not typically list interactions with every specific over-the-counter pain brand. Product labeling emphasizes the importance of reporting all other medicines being used.


Q: Can Levoben be taken at the same time as cold or allergy medicine?

Official product information advises caution or advises against co-administration with sympathomimetics. Sympathomimetics, which are often present in cold or allergy medicines, carry a risk of cardiovascular side effects when combined with this medicine.


Q: Are changes in mood a known side effect of Levoben?

Yes, psychiatric disorders are listed as potential common side effects in the product information. These can include changes such as depression, insomnia, hallucinations, and confusion. Regulatory documents indicate that patients are generally monitored for the development of mental changes.


Q: Does Levoben cause sleepiness or drowsiness?

The official product information indicates that somnolence (drowsiness) is associated with this medication. In rare cases, episodes of sudden sleep onset during daily activities have been reported.


Q: Is Levoben known to interact with herbal supplements like St. John's Wort?

The medicine is strictly contraindicated for use with non-selective Monoamine Oxidase (MAO) inhibitors. Product labeling includes a general recommendation that all medicines and herbal supplements be reported, as some may have MAO-inhibiting properties.


Q: What does the term 'contraindication' mean for Levoben?

A contraindication is an official safety statement that the medicine must not be used in a patient who has a specific pre-existing condition (like closed-angle glaucoma) or is taking certain other medicines. This exclusion is required due to a significant safety risk identified by regulatory bodies.


Q: Are allergic reactions common with Levoben?

Hypersensitivity reactions, with signs such as rash and itching, are noted as possible adverse effects in the official product information. These reactions may occur in susceptible individuals.


Q: How quickly does Levoben usually start to work?

Studies of the immediate-release formulation indicate that the onset of action generally occurs in 30 to 60 minutes. It is noted in official documents that taking the medicine with food can sometimes delay this effect.


Q: What should I know about the long-term use of Levoben?

Official documents indicate that after several years of treatment, patients may experience fluctuations in therapeutic response, often described as 'wearing off' or the 'on-and-off phenomenon.' The development of involuntary movements (dyskinesias) is also noted as a possibility with long-term use.


Q: If I miss taking Levoben, what is the generally suggested approach in official documentation?

The patient information leaflet describes the generally suggested approach to a missed dose as skipping the forgotten dose and taking the next dose at the scheduled time. It specifies that a double dose is not to be taken.


Q: Does Levoben affect the results of any standard medical lab tests?

Yes, official information states that the medicine may cause changes to liver or blood values that are detectable in lab tests. The medicine's metabolites can also cause the urine to become red or dark, which is a known and harmless effect.


Q: What happens if I stop taking Levoben suddenly?

Official documents state that abruptly stopping the medication is not recommended. Doing so may lead to a severe condition called neuroleptic malignant-like syndrome (NMLS).


Q: Is Levoben classified as a controlled substance?

No, regulatory status databases indicate that the medicine is generally classified as a Prescription Only Medicine (POM) or a prescription-only drug. It is not classified as a controlled substance (Schedule I-V).


Q: Is Levoben recommended for breastfeeding mothers?

According to official product information, the safety of the medication for use during breastfeeding has not been established. Product manufacturers generally state that its use during this period is not advised.


Q: Does Levoben have an official warning about driving or operating machinery?

Yes, an official warning exists. Due to the association with somnolence (drowsiness) and episodes of sudden sleep onset, the warning advises that patients experiencing these effects should refrain from driving or operating machinery.


Q: How long does Levoben stay in your system after the last dose?

Official information states that the medicine is almost entirely eliminated by metabolism. The resulting metabolites are primarily excreted in the urine. The half-life of one component is documented as approximately 1.5 hours.


Q: Does Levoben cause weight gain or weight loss?

The adverse reaction profile lists anorexia (loss of appetite) as a common side effect. The documents note that weight decrease within a short period is a symptom that warrants medical evaluation.


Q: What are the official guidelines regarding alcohol consumption while taking Levoben?

Official product information states that alcohol consumption should generally be avoided or limited. This is because alcohol may increase the central nervous system (CNS) side effects of the drug, such as dizziness and drowsiness.


Q: Can Levoben make skin more sensitive to the sun?

The official safety documents do not list photosensitivity or increased sensitivity to the sun as a known or common adverse reaction.


Q: How does Levoben impact the immune system?

The adverse reaction profile lists rare side effects involving the blood and lymphatic system. These have included conditions like leukopenia (a low white blood cell count).


Q: Does Levoben require any special monitoring by a healthcare provider?

Yes, close monitoring is required according to official documents. Official guidelines indicate that periodic checks of blood count and liver function are generally required, along with monitoring for mental changes and impulse control disorders.


Q: Are there specific symptoms that warrant calling a doctor immediately while on Levoben?

The patient information leaflet notes that symptoms requiring urgent medical attention include signs of a neuroleptic malignant-like syndrome, new or worsening psychiatric symptoms, irregular heartbeat, and signs of bleeding (e.g., black stools).


Q: Can Levoben be split or crushed if I have trouble swallowing pills?

Official product information specifies that prolonged-release formulations should generally be swallowed whole without crushing or chewing. However, certain dispersible tablets are specifically designed to be dissolved in water before taking.


Q: Is Levoben related to steroids in any way?

No. The medicine is classified as an Anti-Parkinson Agent and is a combination of a dopamine precursor and a decarboxylase inhibitor. It is chemically and functionally unrelated to steroids.


Q: Do studies suggest Levoben is more effective in men or women?

Specific differences in efficacy between men and women are generally not detailed in the summary of product characteristics or patient information leaflets.


Q: Is Levoben habit-forming?

While not formally classified as habit-forming, the medicine has been associated with Dopaminergic Dysregulation Syndrome (DDS). This syndrome involves excessive or compulsive use of the drug.


Q: Are patients with diabetes able to take Levoben?

Official product information generally advises patients with diabetes to inform their doctor. The official documentation notes that blood sugar monitoring may be required more frequently for patients with diabetes.


Q: How does the body typically eliminate Levoben?

The body eliminates the medicine primarily by metabolism. The resulting metabolites are mainly excreted in the urine and to a smaller extent in the feces.


Q: Is there a generic version of Levoben available?

Yes, the active combination of levodopa and benserazide is widely available as a generic medicine from various manufacturers.


Q: Does Levoben require a prescription?

Yes, in most jurisdictions, the medicine is legally designated as a Prescription Only Medicine (POM) or equivalent and requires a prescription.

How should Levoben be stored and disposed of?

The storage and disposal of Levoben (levodopa/benserazide) tablets are strictly governed by official regulatory requirements to maintain product quality and safety.

Official Storage Requirements

Levoben must be stored at a temperature not exceeding 25 C (77 F). To ensure stability, the tablets must be kept protected from light and moisture at all times. This necessitates storing the medication in its original container and ensuring the container is kept tightly closed.

Safety and Disposal Rules

For child safety, Levoben must be stored out of the sight and reach of children. Regarding disposal, any unused or expired medicinal product or associated waste material must be discarded in accordance with local pharmaceutical waste regulations. The product should not be disposed of using household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levoben found in:

A-Z Index: